RPRX - Royalty Pharma plc

QQQ $ 460.52 $ 1.43 (0.31 %)

DIA $ 410.44 $ 0.19 (0.05 %)

SPY $ 550.83 $ -1.25 (-0.23 %)

TLT $ 98.96 $ 1.21 (1.24 %)

GLD $ 230.43 $ 0.14 (0.06 %)

Previous Close

$ 29.27

Open

$ 28.91

Bid

$ 29.27 x 200

Ask

-- x --

Day's Range

$ 28.89 - $ 29.33

52 Week Range

$ 25.01 - $ 31.18

Volume

1,851,417

Average Volume

Market Cap

17.14B

Beta (5Y Monthly)

$ 0.60

PE Ratio (TTM)

$ 25.46

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.03)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	02-15-2024	12-31-2023	10-K
4	11-08-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	02-15-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	02-15-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-11-2021	06-30-2021	10-Q
14	05-11-2021	03-31-2021	10-Q
15	02-24-2021	12-31-2020	10-K
16	11-12-2020	09-30-2020	10-Q
17	08-12-2020	06-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

rare-disease-focused-ascendis-pharma-stock-falls-on-underwhelming-q2-earnings-guidance-cut

Rare Disease-Focused Ascendis Pharma Stock...
09/04/2024 13:09:44

Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million d...

Ascendis Pharma Subsidiary Enters $150M Ca...
09/03/2024 21:14:07

jim-cramer-this-financial-stock-is-a-buy-core-scientific-is-a-very-overvalued-situation

Jim Cramer: This Financial Stock Is A Buy,...
08/16/2024 13:28:17

Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."

Goldman Sachs Maintains Buy on Royalty Pha...
08/14/2024 11:10:42

Goldman Sachs analyst Chris Shibutani maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50...

Royalty Pharma shares are trading lower af...
08/08/2024 14:45:45

Royalty Pharma Q2 Adj $0.96 Misses $0.99 E...
08/08/2024 11:03:47

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $0.96 per share which missed the analyst consensus estimate of $0.9...

Morgan Stanley Maintains Overweight on Roy...
07/11/2024 17:16:39

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target fr...

wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-high-dividend-yields

Wall Street's Most Accurate Analysts Spotl...
06/12/2024 13:15:52

Royalty Pharma Prices Offering Of $1.5B Of...
06/03/2024 21:18:40

The offering is expected to close on June 10, 2024. Royalty Pharma intends to use the net proceeds from the Notes for general c...

UBS Downgrades Royalty Pharma to Neutral, ...
06/03/2024 15:50:14

UBS analyst Ashwani Verma downgrades Royalty Pharma (NASDAQ:RPRX) from Buy to Neutral and announces $28 price target.

why-is-agios-pharmaceuticals-stock-trading-higher-on-tuesday

Why Is Agios Pharmaceuticals Stock Trading...
05/28/2024 17:00:41

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 mi...

Royalty Pharma Acquires Interest In Agios ...
05/28/2024 11:17:29

heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-uncertainty-analysts-observe

Heart Disease-Focused Cytokinetics Operati...
05/23/2024 18:30:40

Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's comme...

Cytokinetics And Royalty Pharma Enter Fund...
05/22/2024 20:02:52

Royalty Pharma To Acquire Royalties And Mi...
05/09/2024 11:20:42

Under the terms of ImmuNext's licensing agreement with Sanofi, ImmuNext is entitled to receive an upward tiering net royalt...

Royalty Pharma Sees FY24 Portfolio Receipt...
05/09/2024 11:05:34

Royalty Pharma Q1 Sales $568.00M Miss $663...
05/09/2024 11:02:34

Royalty Pharma (NASDAQ:RPRX) reported quarterly sales of $568.00 million which missed the analyst consensus estimate of $663.22...

amgen-reports-better-than-expected-q1-results-50m-milestone-payment

Amgen Reports Better-Than-Expected Q1 Resu...
05/02/2024 21:44:40

Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company s...

Arrowhead Pharmaceuticals Earns $50M Miles...
05/02/2024 20:39:45

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced a $50 million milestone payment was received from Royalty Pharma ...

B of A Securities Maintains Buy on Royalty...
04/12/2024 12:01:57

B of A Securities analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and lowers the price target from $...